Welcome to our dedicated page for RECURSION PHARMACEUTICALS SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Recursion Pharmaceuticals, Inc. filings document the regulatory record for a clinical-stage TechBio company advancing investigational medicines through an AI-native discovery and development platform. Its 8-K reports disclose operating results, financial condition, Regulation FD presentations, clinical and pipeline updates, partner milestones and material corporate events.
Proxy materials cover annual-meeting matters, director elections, executive compensation and governance practices. Other filings include leadership-transition disclosures, shelf-registration and prospectus-supplement records for Class A common stock, and capital-structure disclosures tied to shares issued under the Tempus master agreement.
Recursion Pharmaceuticals (RXRX) director Blake Borgeson received new equity compensation grants on June 18, 2025. The insider was awarded:
- 22,016 restricted stock units (RSUs) that will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
- 44,031 stock options with an exercise price of $5.11, exercisable under the same vesting schedule as the RSUs
Following these transactions, Borgeson directly owns 7,089,863 shares of Class A Common Stock plus the newly granted options. The equity grants were made automatically pursuant to the company's Outside Director Compensation Policy. All awards are subject to continued service requirements. The filing was submitted by Jonathan Golightly as attorney-in-fact on June 23, 2025.
Recursion Pharmaceuticals (RXRX) director Franziska Michor received new equity compensation on June 18, 2025, consisting of two components:
- 22,016 restricted stock units (RSUs) granted under the Outside Director Compensation Policy, which will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
- 44,031 stock options with an exercise price of $5.11, exercisable until June 18, 2035, vesting on the same schedule as the RSUs
Following these transactions, Michor directly owns 127,053 shares of Class A Common Stock and 44,031 stock options. Both grants are subject to continued service as a director. This filing represents standard board of director equity compensation and indicates the company's commitment to aligning director interests with shareholders through equity-based compensation.
Recursion Pharmaceuticals (RXRX) Director Robert Hershberg received new equity compensation grants on June 18, 2025. The awards consist of:
- 22,016 restricted stock units (RSUs) that will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
- Stock options to purchase 44,031 shares at an exercise price of $5.11 per share, vesting on the same schedule as the RSUs
Following these transactions, Hershberg directly owns 73,732 shares of Class A Common Stock and 44,031 stock options. These equity grants were made automatically under the company's Outside Director Compensation Policy and are subject to continued service requirements. The filing indicates standard insider trading reporting compliance under Section 16(a) of the Securities Exchange Act.
Recursion Pharmaceuticals (RXRX) Director Zavain Dar received new equity compensation grants on June 18, 2025, consisting of:
- 22,016 restricted stock units (RSUs) that will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
- 44,031 stock options with an exercise price of $5.11, exercisable until June 18, 2035, vesting on the same schedule as the RSUs
Following these transactions, Dar directly owns 132,893 shares of Class A Common Stock and 44,031 stock options. Both grants are subject to continued service as a director. These awards were automatically granted according to the company's Outside Director Compensation Policy, representing standard board compensation arrangements.
Recursion Pharmaceuticals director Namandje Bumpus received new equity compensation grants on June 18, 2025, consisting of:
- 11,008 restricted stock units (RSUs) that will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
- 22,016 stock options with an exercise price of $5.11, exercisable until June 18, 2035, vesting on the same schedule as the RSUs
Following these transactions, Bumpus directly owns 47,557 shares of Class A Common Stock and 22,016 stock options. Both grants are subject to continued service as a director. These equity awards were automatically granted according to the company's Outside Director Compensation Policy, representing standard board compensation rather than open market transactions.
Dean Y. Li, Director at Recursion Pharmaceuticals (RXRX), reported significant insider transactions on June 18, 2025:
- Acquired 22,016 restricted stock units (RSUs) at $0, which vest on June 18, 2026 or before the 2026 Annual Meeting
- Received 44,031 stock options with exercise price of $5.11, expiring June 18, 2035
Li's total beneficial ownership includes:
- 1,234,618 shares held directly (including 1,132,815 shares transferred from GRAT)
- 1,980,029 shares held indirectly through various trusts: - 1,422,048 via Revocable Trust - 136,981 via GRAT - 421,000 via Family Trust
These grants were made automatically under the company's Outside Director Compensation Policy, subject to continued service.
Recursion Pharmaceuticals (RXRX) director Elaine D. Sun received new equity compensation grants on June 18, 2025, consisting of:
- 11,008 restricted stock units (RSUs) that will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
- 22,016 stock options with an exercise price of $5.11, exercisable until June 18, 2035, vesting on the same schedule as the RSUs
Following these transactions, Sun directly owns 47,557 shares of Class A Common Stock and 22,016 stock options. Both grants are subject to continued service as a director. These equity awards were automatically granted according to the company's Outside Director Compensation Policy, representing standard board compensation arrangements.
Ben R Taylor, Chief Financial Officer of Recursion Pharmaceuticals (RXRX), reported multiple securities transactions and holdings in a Form 4 filing:
Key Transaction: On June 16, 2025, Taylor disposed of 7,057 shares of Class A Common Stock at $4.92 per share through a tax withholding transaction (F code) related to RSU settlement. Following this transaction, Taylor directly owns 823,134 shares.
Stock Option Holdings:
- 70,037 options at $7.25 (expires 2035)
- 740,686 options at $6.09 (expires 2034)
- 81,154 options at $0.14 (expires 2031)
- 92,748 options at $0.06 (expires 2031)
- 289,837 options at $0.04 (expires 2030)
All options have various vesting schedules ranging from monthly to annual installments, subject to continued service requirements.